Fixed-duration Calquence-based regimens approved in EU for 1L CLL patients based on AMPLIFY Ph 3 trial results June 11, 2025
EC Approves ADCETRIS® (brentuximab vedotin) for the Treatment of 1L Patients with Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD June 10, 2025
European Commission Approves SC Formulation of Opdivo Across Multiple Solid Tumor Indications June 3, 2025
NMPA Approves Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer June 3, 2025
NMPA approves Minjuvi (Tafasitamab) + Lenalidomide for the treatment of Adult Patients with R/R DLBCL in China May 27, 2025
EU approved Neoadjuvant Opdivo + Chemo Followed by Adjuvant Opdivo for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% based on CheckMate-77T trial results May 21, 2025
FDA Approves EMRELIS (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced NSCLC With High c-Met Protein Overexpression May 21, 2025
FDA Approves Zynyz (retifanlimab-dlwr) for 1L Treatment of Advanced Anal Cancer Patients May 21, 2025
Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of R/R multiple myeloma May 21, 2025
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer patients May 13, 2025
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of R/R Multiple Myeloma May 6, 2025
MHRA grants conditional marketing authorisation for AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients with R/R B-ALL April 30, 2025
Ivonescimab Receives NMPA Approval for 1L Treatment of PD-L1-Positive NSCLC, Based on Ph 3 Trial Demonstrating Superior Efficacy Over Keytruda April 30, 2025
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in R/R multiple myeloma April 22, 2025
US FDA Grants Full Approval of VITRAKVI (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors April 16, 2025
DATROWAY Approved in the EU for Patients with Previously Treated Metastatic HR+ve, HER2-neg Breast Cancer April 15, 2025
FDA Approves Opdivo + Yervoy as a Treatment for Patients with 1L MSI-H or dMMR Unresectable or Metastatic CRC April 15, 2025
Imfinzi-based perioperative regimen approved in the EU for resectable NSCLC based on AEGEAN Ph 3 trial results April 8, 2025
European Commission approves SC RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated NSCLC April 8, 2025
